AMH (Anti-Müllerian Hormone): Test, Levels, and Fertility

An AMH test has become one of the most-ordered labs in reproductive medicine, but it is also one of the most misinterpreted. Anti-Müllerian hormone is produced by small follicles in the ovary and gives a rough measure of how many eggs are still in the reserve. It does not measure egg quality, it is not a reliable predictor of natural conception, and it does not set a deadline. Used in the right context, AMH helps doctors plan fertility treatment. Used outside that context, it often causes more anxiety than insight.

This guide walks through what AMH actually measures, how to interpret levels by age, what the test cannot tell you, and when ordering it changes care. For broader fertility evaluation, see our overview of female infertility workup and the medical conditions hub.

What AMH Measures

Anti-Müllerian hormone is secreted by the granulosa cells of small antral and preantral follicles in the ovary. The number of these small follicles correlates with the total remaining follicle pool, sometimes called ovarian reserve. AMH is therefore an indirect proxy for how many eggs are left to potentially be recruited in future cycles, per the American Society for Reproductive Medicine (ASRM) resources on ovarian reserve. Crucially, it is a measure of egg quantity, not egg quality, and quality is what matters most for whether an egg can become a healthy pregnancy.

Unlike FSH, which fluctuates significantly across the cycle, AMH levels are relatively stable from day to day. Blood can be drawn at any point in the cycle. AMH gradually declines from the late twenties through menopause, when it becomes undetectable. The decline is not linear; it tends to accelerate in the late thirties and early forties. As MedlinePlus (NIH) notes, AMH testing is used mainly to help assess ovarian reserve and to help plan fertility treatment, not to give a simple yes-or-no answer about fertility.

Typical AMH Levels by Age

Reference ranges vary by lab and assay, but published population data show median AMH values of roughly 4.0 ng/mL in the early twenties, 3.5 at age 30, 2.5 at 35, 1.5 at 38, 1.0 at 40, 0.5 at 42, and below 0.3 by age 45. Values are typically reported in either ng/mL or pmol/L (pmol/L is roughly 7 times the ng/mL value). Because these are population medians, an individual result can fall well outside the “typical” range and still be normal for that person.

Generally accepted thresholds in fertility practice: AMH above roughly 3.5 ng/mL suggests high reserve (and sometimes PCOS), 1.0 to 3.5 is considered normal, 0.5 to 1.0 is reduced, and below 0.5 is significantly diminished. These cutoffs guide IVF protocol selection more than they predict natural conception, and they should be read against your own lab’s age-stratified ranges rather than treated as universal.

How AMH Is Tested

AMH is a simple blood draw with no fasting requirement. Most commercial labs report results in 2 to 5 business days. Cash prices typically run about $50 to $150; insurance often covers AMH when ordered as part of an infertility workup but may not cover it when ordered out of curiosity. Direct-to-consumer mail-in finger-stick AMH tests cost roughly $80 to $200 and are reasonably accurate, though clinic-drawn tests remain the standard for treatment decisions. Prices vary, so confirm the current cost with the lab or clinic.

One important caveat: hormonal contraceptives, particularly combined oral contraceptive pills, can suppress AMH by roughly 20 to 50 percent. If you have been on the pill, ring, or hormonal IUD continuously, your AMH on the test may underestimate your true reserve. Many clinicians advise stopping hormonal contraception for two to three months before testing if AMH will guide major decisions like egg freezing.

What Your Results Actually Mean

AMH is best understood as a quantity measure, not a quality measure. It estimates how many eggs your ovaries are likely to produce in response to fertility medications. Women with low AMH typically retrieve fewer eggs in IVF, may need higher medication doses, and are more likely to have a cycle canceled for poor response. Women with very high AMH respond strongly and need careful monitoring to avoid ovarian hyperstimulation syndrome.

What AMH does not tell you is your chance of conceiving naturally if you are not yet trying. In a widely cited 2017 JAMA study of women aged 30 to 44 attempting natural conception, biomarkers of diminished ovarian reserve, including low AMH, were not associated with a lower probability of conceiving over 6 to 12 months. In other words, AMH is not a reliable predictor of natural fertility for an individual. Egg quality, fallopian tube function, sperm quality, ovulation, and timing matter more for natural conception than the size of the reserve. This is the single most important point to take away: a number on an AMH report should not, by itself, tell you whether you can or cannot get pregnant.

Limitations of AMH Testing

The most important limitation is the egg quality issue. A 38-year-old with an “excellent” AMH still has 38-year-old eggs, with the chromosomal error rates that come with that age. Conversely, a 30-year-old with a low AMH still has 30-year-old eggs, which are mostly chromosomally normal even if fewer in number. AMH says nothing about quality.

Assay variability is another limitation. Different commercial AMH tests do not always produce the same number from the same blood sample. The Roche Elecsys, Beckman Coulter Access, and Ansh Labs assays are among the most widely used; switching labs during fertility treatment can produce confusing trends. Single low values should usually be repeated, ideally on the same assay, before drastic decisions are made.

AMH also performs poorly as a screening test in the general population and does not reliably predict the exact timing of menopause for an individual. The American College of Obstetricians and Gynecologists (ACOG) Committee Opinion 773 explicitly recommends against AMH testing in women who are not actively seeking fertility care, because the results do not reliably predict the timing of menopause or future fertility for an individual woman and can lead to unnecessary anxiety or costly interventions. (Guidance can be updated over time, so confirm the current recommendation with your clinician.)

When AMH Actually Changes Care

Several scenarios genuinely benefit from AMH testing. Before IVF or egg freezing, AMH plus antral follicle count helps reproductive endocrinologists choose a stimulation protocol and set realistic expectations about the number of eggs likely to be retrieved. In women with suspected PCOS, an elevated AMH can support the diagnosis. In women with cancer planning chemotherapy or pelvic radiation, baseline AMH helps guide fertility preservation timing. In recurrent miscarriage or infertility workups, AMH can identify diminished reserve as one factor among many.

The test rarely changes management for a woman in her late twenties or early thirties without infertility, a family history of early menopause, or an oncologic indication. In those cases, AMH most often produces either reassurance that may be falsely confident (a normal level today does not guarantee fertility three years from now) or anxiety that may be falsely catastrophic (a low level does not mean you cannot conceive). Either way, it is easy to over-interpret.

Improving Outcomes With Low AMH

Few interventions reliably raise AMH itself, and AMH is not really the target – outcomes are. Some studies suggest DHEA supplementation may modestly improve IVF response in women with diminished ovarian reserve, but evidence is mixed and any supplement should be taken only under physician supervision, not self-prescribed. CoQ10, vitamin D repletion if deficient, smoking cessation, and maintaining a healthy weight have biological rationale and minimal downside, though none is proven to meaningfully raise AMH.

What changes outcomes more than supplements is the right protocol and the right number of cycles. Women with low AMH often do better with multiple modest IVF cycles than with one large stimulation, banking embryos over time. Donor egg IVF bypasses the reserve issue entirely and is a reasonable conversation when reserve is severely diminished. A fertility specialist can help weigh these options against your age and goals.

Frequently Asked Questions

What is a normal AMH level for my age?

Median AMH falls roughly from 3.5 ng/mL at age 30 to 1.5 at 38 and 0.5 at 42. Anything in the 1.0 to 3.5 range at typical reproductive ages is generally considered normal. Reference ranges vary by laboratory and assay, so always compare your result to the lab’s age-stratified ranges and interpret it with a clinician.

Can I improve my AMH naturally?

The follicle pool is largely fixed at birth and declines with time. Lifestyle measures (not smoking, a healthy weight, vitamin D repletion) support overall reproductive health but do not meaningfully raise AMH. Some women see slightly higher levels after stopping hormonal contraception, because the pill can artificially lower the reading.

Does low AMH mean I cannot get pregnant naturally?

No. AMH measures ovarian reserve, not fertility, and it is not a reliable predictor of natural conception. Many women with low AMH conceive without difficulty as long as they are still ovulating regularly and other factors are favorable. Low AMH does suggest fewer eggs available in IVF and may indicate a shorter reproductive window, but it does not, on its own, mean you cannot conceive.

Does birth control affect my AMH result?

Yes. Combined hormonal contraceptives can suppress AMH by roughly 20 to 50 percent. If you are using the pill, patch, ring, or hormonal IUD, your test result may underestimate your reserve. Many clinicians prefer testing after two to three months off hormonal contraception when the result will guide major decisions.

The Bottom Line

AMH is a useful tool for fertility specialists planning treatment and for women with specific medical reasons to assess ovarian reserve. It is a poor general-purpose fertility predictor and should not, on its own, drive decisions about whether or when to try to conceive. A single number cannot tell you if you are fertile or set a countdown. If you are getting an AMH test, get it through a clinician who can place the result in the full context of your age, cycle history, and reproductive goals.

Sources

• American College of Obstetricians and Gynecologists (ACOG), Committee Opinion 773: The Use of Antimüllerian Hormone in Women Not Seeking Fertility Care – acog.org
• American Society for Reproductive Medicine (ASRM), Ovarian reserve – asrm.org
• MedlinePlus (NIH), Anti-Müllerian Hormone (AMH) Test – medlineplus.gov
• Steiner AZ, et al. Association Between Biomarkers of Ovarian Reserve and Infertility Among Older Women of Reproductive Age. JAMA, 2017 – jamanetwork.com